ACHCAcadia Healthcare Company, Inc.
Acadia Healthcare Company, Inc. (ACHC) operates as a behavioral health provider, offering inpatient and outpatient services through 15 facilities across the U.S. The next catalyst is Dec 15, 2026 — Year-End Behavioral Health Regulatory Scrutiny, which will test the company’s ability to navigate evolving compliance requirements and potential cost pressures in its core service lines.
- The company reported $3.32B in revenue for the fiscal year ending March 31, 2026, but posted a net loss of $1.10B, with a net margin of -33.2% TTM.
- Free cash flow was negative $636M in the trailing twelve months, and debt-to-equity stood at 1.30x.
- Revenue grew 5.0% YoY, but operating leverage remains constrained by high fixed costs and legal exposure.
The Read
8% in response to mixed Q2 results and legal challenges, with a median historical move of about 12%.
The schedule
- Tue15Dec
Review of potential CMS policy updates, reimbursement rates, and compliance standards impacting behavioral health facilities.
- Tue26Jan
Q3 2026 results focusing on margin sustainability, operating leverage, and capital expenditure efficiency.
- Tue27Apr
Full-year 2026 earnings results and initial management outlook for FY2027 revenue and profitability metrics.
- Tue27Jul
First quarter 2027 financial performance and execution check against newly established fiscal year guidance.
- Tue26Oct
Past
- Tue15Sep
Actual outcome: Bear · $29.36 at outcome
Stock rose 7.3% from event to outcome date, aligning with the bear trajectory.
Evaluation of Acadia's $2.66B debt load and refinancing capabilities against recent negative free cash flow generation.
- Tue28Jul
Actual outcome: Mixed · $31.67 at outcome
Acadia Healthcare reported Q2 earnings that beat estimates, driven by higher admissions, and management raised full-year 2026 guidance. However, revenue remained flat year-over-year and the company faced ongoing legal headwinds after a court denied a motion to dismiss a securities class action lawsuit. The combination of positive operational metrics and raised guidance was offset by profit pressures and legal uncertainties, resulting in a muted price reaction.
Market reaction to Acadia Healthcare's Q2 2026 operational performance, margins, and admission trends.
- Wed29Apr
Actual outcome: Bull · $27.85 at outcome
Acadia Healthcare delivered a strong Q1 2026 earnings beat, reporting EPS of $0.37 against estimates of $0.28 and a 7.6% year-over-year revenue increase to $828.8 million. The solid top-line performance, highlighted by 7.3% same-facility revenue growth, helped ease market fears that the massive Q4 2025 loss was indicative of systemic operational failure, pushing the stock well past the bull target.
Acadia Healthcare delivered a strong Q1 2026 earnings beat, reporting EPS of $0.37 against estimates of $0.28 and a 7.6% year-over-year revenue increase to $828.8 million. The solid top-line performance, highlighted by 7.3% same-facility revenue growth, helped ease market fears that the massive Q4 2025 loss was indicative of systemic operational failure, pushing the stock well past the bull target.
